SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin plans to launch 25 products in the US in FY18

13 Feb 2017 Evaluate

Lupin is planning to launch around 25 products in the US in next finance year. The drug major’s focus remains on the speciality drugs business in the US.

The Mumbai-based drug firm launched four products in the US market during the third quarter ended December 31. It received 11 approvals from the USFDA during the period. It now has a portfolio of 128 generic products in the US market.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2457.80 15.45 (0.63%)
07-May-2026 15:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1837.00
Dr. Reddys Lab 1309.40
Cipla 1363.00
Zydus Lifesciences 939.40
Lupin 2457.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×